Stock Market Alert - Just to add to the ugliness of an already ugly day on Wall Street, THLD announced that a phase III clinical trial of Glufosframide for treatment of pancreatic cancer did not meets its endpoint. Volume was extremely heavy on the news, with over 7.1 million shares of the stock changing hands, compared to a normal daily average volume of just over 480k shares traded. The stock plummeted, dropping over 57% to close the regular session at $1.52. The stock currently has a 52 week low of $1.42.
Sorry, the comment form is closed at this time.